Interleukin‐1β/Iinterleukin‐1 receptor‐associated kinase 1 inflammatory signaling contributes to persistent Gankyrin activation during hepatocarcinogenesis

Bo Su, Tao Luo, Junjie Zhu, Jing Fu, Xiaofang Zhao, Lei Chen, Huilu Zhang, Yibin Ren, Lexing Yu, Xiaojun Yang, Mengchao Wu, Gensheng Feng, Shao Li, Yao Chen, Hongyang Wang – 7 October 2014 – Hepatocellular carcinoma (HCC) is a prototype of inflammation‐associated cancer. Oncoprotein Gankyrin, which mostly increases in HCC, plays a critical role in HCC development and metastasis. However, the exact mechanism of Gankyrin up‐regulation in HCC remains unclear.

Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: Results of a longitudinal study

Filipe Nery, Sylvie Chevret, Bertrand Condat, Emmanuelle de Raucourt, Larbi Boudaoud, Pierre‐Emmanuel Rautou, Aurelie Plessier, Dominique Roulot, Cendrine Chaffaut, Valerie Bourcier, Jean‐Claude Trinchet, Dominique‐Charles Valla, on behalf of Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire – 6 October 2014 – In cirrhosis, portal vein thrombosis (PVT) could be a cause or a consequence of the progression of liver disease.

Lineage‐dependent effects of aryl hydrocarbon receptor agonists contribute to liver tumorigenesis

Joshua A. Harrill, Bethany B Parks, Eliane Wauthier, J. Craig Rowlands, Lola M. Reid, Russell S. Thomas – 6 October 2014 – Rodent cancer bioassays indicate that the aryl hydrocarbon receptor (AHR) agonist, 2,3,7,8‐tetracholorodibenzo‐p‐dioxin (TCDD), causes increases in both hepatocytic and cholangiocytic tumors. Effects of AHR activation have been evaluated on rodent hepatic stem cells (rHpSCs) versus their descendants, hepatoblasts (rHBs), two lineage stages of multipotent, hepatic precursors with overlapping but also distinct phenotypic traits.

Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma

Chunping Wang, Huaming Wang, Wuwei Yang, Kaiwen Hu, Hui Xie, Ke‐Qin Hu, Wenlin Bai, Zheng Dong, Yinying Lu, Zhen Zeng, Min Lou, Hong Wang, Xudong Gao, Xiujuan Chang, Linjing An, Jianhui Qu, Jin Li, Yongping Yang – 6 October 2014 – Radiofrequency ablation (RFA) is considered a curative treatment option for hepatocellular carcinoma (HCC). Growing data have demonstrated that cryoablation represents a safe and effective alternative therapy for HCC, but no randomized controlled trial (RCT) has been reported to compare cryoablation with RFA in HCC treatment.

Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation

Wei Zhang, Richard Kim, Cristiano Quintini, Koji Hashimoto, Masato Fujiki, Teresa Diago, Bijan Eghtesad, Charles Miller, John Fung, Ann Tan, K. V. Narayanan Menon, Federico Aucejo – 6 October 2014 – Vascular endothelial growth factor (VEGF) is pivotal in the development of hepatocellular carcinoma (HCC). Studies have demonstrated the prognostic value of circulating VEGF levels in patients undergoing liver resection or locoregional therapy (LRT) for HCC.

Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma

Chunping Wang, Huaming Wang, Wuwei Yang, Kaiwen Hu, Hui Xie, Ke‐Qin Hu, Wenlin Bai, Zheng Dong, Yinying Lu, Zhen Zeng, Min Lou, Hong Wang, Xudong Gao, Xiujuan Chang, Linjing An, Jianhui Qu, Jin Li, Yongping Yang – 6 October 2014 – Radiofrequency ablation (RFA) is considered a curative treatment option for hepatocellular carcinoma (HCC). Growing data have demonstrated that cryoablation represents a safe and effective alternative therapy for HCC, but no randomized controlled trial (RCT) has been reported to compare cryoablation with RFA in HCC treatment.

Subscribe to